These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein. Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483 [TBL] [Abstract][Full Text] [Related]
6. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Syrigos KN; Epenetos AA Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606 [TBL] [Abstract][Full Text] [Related]
7. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug. Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666 [TBL] [Abstract][Full Text] [Related]
10. Antibody-directed enzyme prodrug therapy. Connors TA Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145 [No Abstract] [Full Text] [Related]
11. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Roy P; Waxman DJ Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390 [TBL] [Abstract][Full Text] [Related]
13. Recent developments in gene-directed enzyme prodrug therapy (GDEPT) for cancer. Niculescu-Duvaz I; Cooper RG; Stribbling SM; Heyes JA; Metcalfe JA; Springer CJ Curr Opin Mol Ther; 1999 Aug; 1(4):480-6. PubMed ID: 11713763 [TBL] [Abstract][Full Text] [Related]
14. Tumor targeting: activation of prodrugs by enzyme-monoclonal antibody conjugates. Huennekens FM Trends Biotechnol; 1994 Jun; 12(6):234-9. PubMed ID: 7765070 [TBL] [Abstract][Full Text] [Related]
15. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Both GW Curr Opin Mol Ther; 2009 Aug; 11(4):421-32. PubMed ID: 19649987 [TBL] [Abstract][Full Text] [Related]
16. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688 [TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical drug targeting to the brain. Pardridge WM J Drug Target; 2010 Apr; 18(3):157-67. PubMed ID: 20064077 [TBL] [Abstract][Full Text] [Related]
18. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies. Tietze LF; Krewer B Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031 [TBL] [Abstract][Full Text] [Related]
19. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer. Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329 [TBL] [Abstract][Full Text] [Related]